Published in Blood Weekly, July 26th, 2001
Currently, biochemical, viral, and serological methods are available for screening individuals for HCV. These methods, however, differ in sensitivity and costs. With the HCV infection rate among hemodialysis patients ranging between 8% and 10%, screening this population is a necessity. University of California at Los Angeles (UCLA) researchers report serological screening makes the most sense in terms of cost and sensitivity. Their report was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.